Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status

ConclusionResults suggest reconsidering TAS-102 in patients with ECOG> 0, something that should be investigated in prospective randomized clinical trials.

http://link.springer.com/10.1007/s12094-019-02154-3

Source: Clinical and Translational Oncology - June 16, 2019 Category: Cancer & Oncology Source Type: research